Has Shahed Quyyumi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $373,370 in general payments to Shahed Quyyumi, MD across 1,630 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shahed Quyyumi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shahed Quyyumi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shahed Quyyumi, MD

Endocrinology, Diabetes & Metabolism · Staten Island, NYNPI 1487649885

Payments from drug & device makers

$373,370in general payments, 2019–2025

Across 1,630 payments — averaging $229.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi US Services Inc.$201K
Boehringer Ingelheim$60K
AstraZeneca$47K
Sanofi-aventis U.S. LLC$20K
Lilly USA, LLC$17K
Novo Nordisk$4K
plus $24K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi US Services Inc.	12	$201,134
Boehringer Ingelheim	155	$60,317
AstraZeneca(2 entities)	161	$47,009
Sanofi-aventis U.S. LLC	77	$19,650
Lilly USA, LLC	135	$16,962
Novo Nordisk	251	$4,185
Amgen(2 entities)	109	$3,717
Corcept Therapeutics	16	$3,192
Medtronic(2 entities)	21	$2,178
Mannkind Corporation	83	$1,747
Insulet Corporation	73	$1,585
Bayer	61	$1,272
Dexcom, Inc.	32	$1,021
AbbVie	54	$980
Pfizer	42	$947
Radius Health, Inc.	37	$862
Merck	45	$820
Abbott	30	$812
Amneal Pharmaceuticals LLC	41	$804
Intra-sana Laboratories	6	$380
Xeris Pharmaceuticals, Inc.	17	$338
Ascendis Pharma Endocrinology Inc	11	$332
Johnson & Johnson	22	$279
Esperion Therapeutics, Inc.	17	$254
Amryt Pharma Holdings Ltd	8	$175
Ipsen Biopharmaceuticals, Inc	10	$174
Novartis	9	$168
Tandem Diabetes Care, Inc.	3	$166
Chiesi USA, Inc.	6	$149
GRT US Holding, Inc.	2	$140
IBSA Pharma Inc.	9	$134
Valeritas, Inc.	7	$134
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	8	$131
BETA Bionics, Inc.	2	$128
Tolmar, Inc.	7	$121
BD	5	$111
Recordati_rare_diseases_inc.	4	$86
Amarin Pharma, Inc.	4	$71
Embecta Corp.	3	$64
Almatica Pharma LLC	3	$51
GSK	2	$48
Lifescan, Inc.	3	$42
Eisai Inc.	2	$42
Ultragenyx Pharmaceutical Inc.	2	$35
Intuity Medical Inc	2	$33
Vistapharm, Inc.	2	$33
Sanofi Pasteur Inc.	2	$31
Rhythm Pharmaceuticals, Inc.	1	$30
Cequr Corporation	2	$28
Echosens North America, Inc.	1	$27
Neurocrine Biosciences, Inc.	1	$27
Madrigal Pharmaceuticals	1	$26
Averitas Pharma Inc.	1	$23
Kyowa Kirin, Inc.	1	$23
Bausch Health US, LLC	1	$21
Verity Pharmaceuticals Inc.	1	$20
Regeneron Healthcare Solutions, Inc.	1	$19
Amphastar Pharmaceuticals, Inc.	1	$19
Sequel Med Tech, LLC	1	$17
Antares Pharma, Inc.	1	$15

How this compares

$373,370 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024

$191,005

Medicare patients

857

Services billed

2,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Staten Island

Philip OtterbeckStaten Island$699K
Jeffrey RothmanStaten Island$237K
Robert BuschAlbany$9.1M
Anastasios ManessisNew York$4.4M
Ruth WeinstockSyracuse$3.1M
Adi CohenNew York$2.5M
Ajay ChaudhuriBuffalo$2.4M
Carol LevyNew York$2.2M
Mishaela RubinNew York$2M
Kenneth HershonNew Hyde Park$1.9M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →